Announced Date: 2025-09-05 (September 5, 2025)
Asset Name: HRS-1893
Licensor: Jiangsu Hengrui Pharmaceuticals (China)
Licensee (Buyer): Braveheart Bio, Inc. (US) （NewCo）
.
Asset Modality: Small Molecule
Asset Target: Myosin inhibitor
Potential Indication: obstructive hypertrophic cardiomyopathy (oHCM)
Current Stage: Phase III
.
Scope of Authority:
Hengrui will grant Braveheart Bio the exclusive rights to develop, manufacture, and commercialize HRS-1893 globally, excluding mainland China, Hong Kong, Macao, and Taiwan.
.
Payment Detail:
Upfront payment of $65 million ($32.5 million in cash, and an equivalent of $32.5 million in Braveheart Bio company stock ) ,
Near term payments of $10 billion （after technology transfer）,
Milestone payments up to $1.013 billion,
Total up to $1.088 billion
Royalties on net sales, tiered
.
Link:
